August 04, 2020
Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in multiple myeloma
Media
August 04, 2020
Strongbridge Biopharma plc Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 04, 2020
GenSight Biologics draws down the €4 million second tranche of bonds from Kreos Capital
July 30, 2020
Nordic Nanovector Announces EU Patent Granted Covering the Use of Alpha37
July 30, 2020
GenSight Biologics Reports Interim Financial Results for the First Half of 2020 and Provides Operational Update
July 28, 2020
Strongbridge Biopharma plc to Host Second Quarter 2020 Financial Results Conference Call on August 4, 2020
July 27, 2020
Vicore Pharma doses first COVID-19 patient in the ATTRACT study in India
July 27, 2020
CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy
July 22, 2020
GenSight Biologics reports final REALITY natural history study results confirming poor spontaneous recovery for LHON patients with ND4 mutation
July 17, 2020
Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for the Front-Line Treatment of TP53 Mutant Acute Myeloid Leukemia (AML)